A Phase 1 interventional study of BIIB800 and Actemra in Healthy Volunteer, sponsored by Biogen. Completed at 4 sites in 2 countries. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-06.
Sponsored by Biogen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to show equivalence in pharmacokinetics (PK) of BIIB800 and Actemra following SC administration of a single dose to healthy male participants. The secondary objective of the study is to evaluate PK over time, clinical safety, pharmacodynamic (PD) profiles and immunogenicity of BIIB800 and Actemra.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of BIIB800 via autoinjector, administered SC in the outer area of the upper arm on Day 1 of the study.
Drug: BIIB800
Participants will receive a single dose of Actemra via autoinjector, administered SC in the outer area of the upper arm on Day 1 of the study.
Drug: Actemra
Maximum Observed Serum Concentration (Cmax) of Tocilizumab
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tocilizumab
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Area Under the Concentration-Time Curve up to the Last Measurable Concentration (AUC0-t) of Tocilizumab
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Time to Reach Cmax (Tmax) of BIIB800 and Tocilizumab
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Apparent Total Body Clearance (CL/F) of BIIB800 and Actemra
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Apparent Terminal Half-Life (t1/2) of BIIB800 and Actemra
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious AEs (TESAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant who has received a pharmaceutical product, regardless of causal relationship with the product. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease which is temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE that starts during or after dosing or starts prior to dosing and increases in severity after dosing. An SAE is any untoward medical occurrence that results in death, in the view of the Investigator, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, is a medically important event.
Time frame: From the first dose of study drug up to the end of the study (up to Day 57)
Area Under the Effect-Time Curve (AUE) of Soluble Interleukin-6-Receptor (sIL-6R)
sIL-6R levels were determined using a validated immunoassay method based on ProteinSimple Ella.
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Maximum Observed Effect (Emax) of sIL-6R
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Time to Emax (tEmax) of sIL-6R
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
AUE of High Sensitivity C-Reactive Protein (hsCRP)
hsCRP was determined using a particle enhanced immunoturbidometric assay.
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Minimum Observed Effect (Emin) of hsCRP
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Time to Emin (tEmin) of hsCRP
Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Number of Participants With Positive Tocilizumab Anti-drug Antibodies (ADA) and Neutralizing Antibodies (nAb) Status
The ADA-positive status was determined as a participant with either a pre-existing ADA-positive status (an ADA-positive sample at baseline \[prior to administration of study treatment\]) or a treatment-induced ADA-positive status (a participant with a negative ADA sample at baseline \[pre-dose\] and at least one ADA-positive sample after the administration of the study treatment. The nAb-positive status was determined in the same manner that of ADA status. ADA and nAb were analyzed in human serum using validated electrochemiluminescence (ECL) assays based on the MesoScale Discovery platform and were measured using validated ECL methods.
Time frame: Day 1 to Day 57
Geometric Mean Titer of Anti-drug Antibodies (ADA)
ADA titre was defined as a quasi-quantitative expression of the level of ADA in a sample.
Time frame: Pre-dose, Days 15, 29, 57
Healthy male participants were enrolled in this study from 02 January 2024 to 04 October 2024 at investigative sites in the US and UK.
| Milestone | BIIB800 | Actemra |
|---|---|---|
| Started | 150 | 150 |
| Completed | 149 | 148 |
| Not completed | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| micrograms per milliter (μg/mL) | BIIB800 | Actemra |
|---|---|---|
| Maximum Observed Serum Concentration (Cmax) of Tocilizumab | 10.5 ± 43.3 | 10.0 ± 41.3 |
| hours (h)*μg/ mL | BIIB800 | Actemra |
|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tocilizumab | 2380 ± 44.9 | 2240 ± 41.1 |
| h*μg/ mL | BIIB800 | Actemra |
|---|---|---|
| Area Under the Concentration-Time Curve up to the Last Measurable Concentration (AUC0-t) of Tocilizumab | 2120 ± 45.9 | 2000 ± 44.0 |
| hours | BIIB800 | Actemra |
|---|---|---|
| Time to Reach Cmax (Tmax) of BIIB800 and Tocilizumab | 84.0 (12.1 to 241) | 96.0 (24.0 to 168) |
| Liter per hour (L/h) | BIIB800 | Actemra |
|---|---|---|
| Apparent Total Body Clearance (CL/F) of BIIB800 and Actemra | 0.0680 ± 44.9 | 0.0723 ± 41.1 |
| hours | BIIB800 | Actemra |
|---|---|---|
| Apparent Terminal Half-Life (t1/2) of BIIB800 and Actemra | 68.5 (36.3 to 202) | 68.3 (33.0 to 151) |
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant who has received a pharmaceutical product, regardless of causal relationship with the product. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease which is temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE that starts during or after dosing or starts prior to dosing and increases in severity after dosing. An SAE is any untoward medical occurrence that results in death, in the view of the Investigator, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, is a medically important event.
| Participants | BIIB800 | Actemra |
|---|---|---|
| TEAEs | 76 | 86 |
| TESAEs | 2 | 0 |
sIL-6R levels were determined using a validated immunoassay method based on ProteinSimple Ella.
| hours*nanograms per milliliter (h*ng/mL) | BIIB800 | Actemra |
|---|---|---|
| Area Under the Effect-Time Curve (AUE) of Soluble Interleukin-6-Receptor (sIL-6R) | 209000 ± 68400 | 202000 ± 58200 |
| ng/mL | BIIB800 | Actemra |
|---|---|---|
| Maximum Observed Effect (Emax) of sIL-6R | 459 ± 99.1 | 452 ± 90.6 |
| hours | BIIB800 | Actemra |
|---|---|---|
| Time to Emax (tEmax) of sIL-6R | 336 (4.00 to 1370) | 336 (144 to 1350) |
hsCRP was determined using a particle enhanced immunoturbidometric assay.
| hours*milligrams per liter (h*mg/L) | BIIB800 | Actemra |
|---|---|---|
| AUE of High Sensitivity C-Reactive Protein (hsCRP) | 1190 ± 1480 | 1780 ± 2570 |
| milligrams per liter (mg/L) | BIIB800 | Actemra |
|---|---|---|
| Minimum Observed Effect (Emin) of hsCRP | 0.133 ± 0.124 | 0.131 ± 0.105 |
| hours | BIIB800 | Actemra |
|---|---|---|
| Time to Emin (tEmin) of hsCRP | 72.0 (0 to 483) | 96.0 (0 to 338) |
The ADA-positive status was determined as a participant with either a pre-existing ADA-positive status (an ADA-positive sample at baseline \[prior to administration of study treatment\]) or a treatment-induced ADA-positive status (a participant with a negative ADA sample at baseline \[pre-dose\] and at least one ADA-positive sample after the administration of the study treatment. The nAb-positive status was determined in the same manner that of ADA status. ADA and nAb were analyzed in human serum using validated electrochemiluminescence (ECL) assays based on the MesoScale Discovery platform and were measured using validated ECL methods.
| Participants | BIIB800 | Actemra |
|---|---|---|
| ADA | 26 | 12 |
| nAb | 21 | 9 |
ADA titre was defined as a quasi-quantitative expression of the level of ADA in a sample.
| titre | BIIB800 | Actemra |
|---|---|---|
| Day 15 | — | 160.0 ± 0.0 |
| Day 29 | 201.6 ± 41.7 | 254.0 ± 94.7 |
| Day 57 | 477.3 ± 96.7 | 452.5 ± 152.4 |
Collected over From the first dose of study drug up to the end of the study (up to Day 57). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BIIB800 | 0/150 (0%) | 2/150 (1.3%) | 75/150 (50%) |
| Actemra | 0/150 (0%) | 0/150 (0%) | 86/150 (57.3%) |
| Event | BIIB800 | Actemra |
|---|---|---|
| Jaw fractureInjury, poisoning and procedural complications | 1/150 | 0/150 |
| ParesthesiaNervous system disorders | 1/150 | 0/150 |
| Event | BIIB800 | Actemra |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 3/150 | 25/150 |
| HeadacheNervous system disorders | 13/150 | 16/150 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 8/150 | 7/150 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 8/150 | 5/150 |
| FatigueGeneral disorders | 5/150 | 8/150 |
| Back painMusculoskeletal and connective tissue disorders | 4/150 | 7/150 |
| White blood cell count decreasedInvestigations | 1/150 | 7/150 |
| Injection site bruisingGeneral disorders | 6/150 | 5/150 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/150 | 6/150 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/150 | 2/150 |
The all participants analysis set (APAS) included all participants who provided informed consent and had any protocol-led assessment recorded in the study clinical database (i.e., excluded screen failures).
| Age, Continuous(years) | BIIB800 | Actemra | Total |
|---|---|---|---|
| Mean | 33.9 ± 9.34 | 34.0 ± 9.93 | 33.9 ± 9.62 |
| Sex: Female, Male(Participants) | BIIB800 | Actemra | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 150 | 150 | 300 |
| Ethnicity (NIH/OMB)(Participants) | BIIB800 | Actemra | Total |
|---|---|---|---|
| Hispanic or Latino | 20 | 19 | 39 |
| Not Hispanic or Latino | 130 | 130 | 260 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | BIIB800 | Actemra | Total |
|---|---|---|---|
| Race — White | 108 | 108 | 216 |
| Race — Black or African American | 23 | 25 | 48 |
| Race — Asian | 10 | 11 | 21 |
| Race — Multiple | 8 | 5 | 13 |
| Race — American Indian or Alaska Native | 0 | 1 | 1 |
| Race — Other | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Ran from Jan 2024 to primary completion in Sep 2024, 8 months.
Results were first posted in Oct 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab